Vericel Corp (VCEL) Form 10-Q — Jul 30, 2026
Vericel reported strong financial results for the second quarter of 2026, with total revenue rising 22.5% year-over-year to $77.5 million for the quarter and 25.9% to $145.9 million for the six-month period. The company achieved a milestone of profitability in the second quarter with net income of $2.2 million, a significant turnaround from a net loss of $0.6 million in the prior-year quarter, while narrowing its net loss for the six-month period to $4.1 million. Strategic developments included the execution of a ten-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $196.9 million.
Key figures
- Revenue
- 145882
- Total Debt
- 0
- Cash Position
- 125358
- Revenue Growth
- 25.9%
- Q2 2026 net income
- 2206
- Six month revenue 2026
- 145882
- Barda agreement value millions
- 196.9
- Share repurchase authorization millions
- 200
Price after filing
Close on the filing date to close N calendar days later (from $46.71). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.